Figure 1
Blood lipid changes in each group. We obtained 160 female Balb/c mice (8 weeks old) and randomly selected 40 mice as the normal control group, which were given a standard chow diet for 8 weeks. The remaining 120 mice were given a high sugar and high fat diet for 8 weeks. These mice were then intraperitoneally injected with 80 mg/kg of 2% streptozotocin twice. Mice with a blood glucose concentration ≥ 16.7 mM were considered diabetes. Diabetic mice were randomly divided into six groups (n = 20 mice per group). There were three mono-dose groups that were injected once in the tail vein on day 1: the β2GP I group (20 μg); the reduced β2GP I group (20 μg); and the diabetic control group treated with PBS. We used PBS as the vehicle for β2GP I and reduced β2GP I. We also had three complex-dose groups that were injected twice in the tail vein on days 1 and 22: the β2GP I group (20 μg each injection), the reduced β2GP I group (20 μg each injection); and the diabetic control group (PBS). The 40 normal control mice were randomly divided into two groups (n = 20 mice per group), so that there were controls for the mono- and complex-dose groups, and injected with PBS. The blood lipids were tested at day 22 in mono-dose groups and at day 43 in complex-dose groups. A. Plasma concentration of triglycerides (TG). B. Plasma concentration of total cholesterol (TC). C. Plasma concentration of low-density lipoprotein cholesterol (LDL-c). D. Plasma concentration of high-density lipoprotein cholesterol (HDL-c). Values are presented as mean ± SD. * P < 0.05 vs. normal controls; # P < 0.05 vs. diabetic controls; @ P < 0.05 vs. reduced β2GP I (R-β2GP I); and &P < 0.05 vs. β2GP I.